Safety Study of ORG 34517 for Major Depression With Psychotic Features
Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
Patients suffering from Major Depressive Disorder with Psychotic features who have received
no changes in their medications in the previous two weeks will receive "usual" treatment of
antidepressants, antipsychotics and/or mood stabilizers and adjunct therapy using ORG34517.
The patient will be hospitalized for up to two weeks to monitor their medications and
progress and will return to the site for periodic assessments.